A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Open to people ages 18 years and up

• Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting.
• Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting
• Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1
• Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations
• Other protocol defined inclusion criteria may apply

• If Adverse Events related to previous therapies have not recovered to less than Grade 1 by National Cancer Institute - Common Terminology Criteria for Adverse Events version 6.0
• Participant has a history of additional malignancy within 3 years before randomization
• Participants with known brain metastases
• Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization
• Participants with ileus of more than Grade 1, or chronic inflammatory bowel disease (example ulcerative colitis, Crohn's disease) and/or bowel obstruction, or participants with chronic gastrointestinal disorders that, in the Investigator's opinion, might significantly interfere with proper absorption of the study treatments
• Other protocol defined exclusion criteria may apply